Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review

    Access Status
    Fulltext not available
    Authors
    Chow, C.
    Thakkar, J.
    Bennett, A.
    Hillis, G.
    Burke, M.
    Usherwood, T.
    Vo, K.
    Rogers, K.
    Atkins, E.
    Webster, R.
    Chou, M.
    Dehbi, H.
    Salam, A.
    Patel, A.
    Neal, B.
    Peiris, D.
    Krum, H.
    Chalmers, J.
    Nelson, M.
    Reid, Christopher
    Woodward, M.
    Hilmer, S.
    Thom, S.
    Rodgers, A.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Chow, C. and Thakkar, J. and Bennett, A. and Hillis, G. and Burke, M. and Usherwood, T. and Vo, K. et al. 2017. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. The Lancet. 389 (10073): pp. 1035-1042.
    Source Title
    The Lancet
    DOI
    10.1016/S0140-6736(17)30260-X
    ISSN
    0140-6736
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/62266
    Collection
    • Curtin Research Publications
    Abstract

    © 2017 Elsevier Ltd Background Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm Hg on average. There is a pressing need for blood pressure-control strategies with improved efficacy and tolerability. We aimed to assess whether ultra-low-dose combination therapy could meet these needs. Methods We did a randomised, placebo-controlled, double-blind, crossover trial of a quadpill—a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbesartan 37·5 mg, amlodipine 1·25 mg, hydrochlorothiazide 6·25 mg, and atenolol 12·5 mg). Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners. Participants were randomly allocated by computer to either the quadpill or matching placebo for 4 weeks; this treatment was followed by a 2-week washout, then the other study treatment was administered for 4 weeks. Study staff and participants were unaware of treatment allocations, and masking was achieved by use of identical opaque capsules. The primary outcome was placebo-corrected 24-h systolic ambulatory blood pressure reduction after 4 weeks and analysis was by intention to treat. We also did a systematic review of trials evaluating the efficacy and safety of quarter-standard-dose blood pressure-lowering therapy against placebo. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12614001057673. The trial ended after 1 year and this report presents the final analysis. Findings Between November, 2014, and December, 2015, 55 patients were screened for our randomised trial, of whom 21 underwent randomisation. Mean age of participants was 58 years (SD 11) and mean baseline office and 24-h systolic and diastolic blood pressure levels were 154 (14)/90 (11) mm Hg and 140 (9)/87 (8) mm Hg, respectively. One individual declined participation after randomisation and two patients dropped out for administrative reasons. The placebo-corrected reduction in systolic 24-h blood pressure with the quadpill was 19 mm Hg (95% CI 14–23), and office blood pressure was reduced by 22/13 mm Hg (p < 0·0001). During quadpill treatment, 18 (100%) of 18 participants achieved office blood pressure less than 140/90 mm Hg, compared with six (33%) of 18 during placebo treatment (p=0·0013). There were no serious adverse events and all patients reported that the quadpill was easy to swallow. Our systematic review identified 36 trials (n=4721 participants) of one drug at quarter-dose and six trials (n=312) of two drugs at quarter-dose, against placebo. The pooled placebo-corrected blood pressure-lowering effects were 5/2 mm Hg and 7/5 mm Hg, respectively (both p < 0·0001), and there were no side-effects from either regimen. Interpretation The findings of our small trial in the context of previous randomised evidence suggest that the benefits of quarter-dose therapy could be additive across classes and might confer a clinically important reduction in blood pressure. Further examination of the quadpill concept is needed to investigate effectiveness against usual treatment options and longer term tolerability. Funding National Heart Foundation, Australia; University of Sydney; and National Health and Medical Research Council of Australia.

    Related items

    Showing items related by title, author, creator and subject.

    • Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
      Bennett, A.; Chow, C.; Chou, M.; Dehbi, H.; Webster, R.; Salam, A.; Patel, A.; Neal, B.; Peiris, D.; Thakkar, J.; Chalmers, J.; Nelson, M.; Reid, Christopher; Hillis, G.; Woodward, M.; Hilmer, S.; Usherwood, T.; Thom, S.; Rodgers, A. (2017)
      There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, ...
    • Clinical and research developments in the treatment of paediatric obsessive-compulsive disorder
      Watson, Hunna J (2007)
      It is of crucial importance to identify and disseminate effective treatments for paediatric obsessive-compulsive disorder (OCD). OCD is time-consuming and distressing, and can substantially disable functioning at school, ...
    • Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
      Lonn, E.; Bosch, J.; López-Jaramillo, P.; Zhu, J.; Liu, L.; Pais, P.; Diaz, R.; Xavier, D.; Sliwa, K.; Dans, A.; Avezum, A.; Piegas, L.; Keltai, K.; Keltai, M.; Chazova, I.; Peters, R.; Held, C.; Yusoff, K.; Lewis, B.; Jansky, P.; Parkhomenko, A.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Leiter, L.; Molina, D.; McKelvie, R.; Pogue, J.; Wilkinson, J.; Jung, H.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2016)
      BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.